Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Nagayama, Kosuke ^a   Kyotani, Yoji ^a   Zhao, Jing ^a   Ito, Satoyasu ^a   Ozawa, Kentaro ^a   Bolstad, Francesco A ^a   Yoshizumi, Masanori ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; AORTA; ARTICLE; CELL COUNTING; CELL CULTURE; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MIGRATION INHIBITION; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; WOUND HEALING; WST-8 ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; MALE; METABOLISM; PHOSPHORYLATION; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PEPTIDES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VENOMS;

EID: 84945914015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137960     Document Type: Article

References (34)

1. Ross R. Atherosclerosis - an inflammatory disease. New Eng J Med 1999; 340: 115-126. PMID: 9887164
2. Berk BC, Haendeler J, Sottile J. Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest 2000; 105: 1525-152. PMID: 10841510
3. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672. PMID: 11121512
4. Schmitz U, Berk BC. Angiotensin II signal transduction: Stimulation of multiple mitogen-activated protein kinase pathways. Trend Endocrinol Metabol 1997; 8: 261-266.
5. Tsuda T, Kawahara Y, Ishida Y, Koide M, Shii K, Yokoyama M. Angiotensin II stimulates two myelin basic protein/microtubule-associated protein 2 kinases in cultured vascular smooth muscle cells. Circ Res 1992; 71: 620-630. PMID: 1323434
6. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, et al. Differential activation of mitogenactivated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000; 20: 940-948. PMID: 10764657
7. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001; 50: 2237-2243. PMID: 11574404
8. Drucker DJ. The biology of incretin hormones. Cell Metabol 2006; 3: 153-165.
9. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157. PMID: 17498508
10. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagonlike peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009; 157: 1340-1351. doi: 10.1111/j.1476-5381.2009.00376.x PMID: 19681866
11. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596. PMID: 7628397
12. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405. PMID: 1313797
13. Kang JH, Chang SY, Jang HJ, Kim DB, Ryu GR, Ko SH, et al. Exendin-4 inhibits interleukin-1betainduced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells. J Endocrinol 2009; 202: 65-75. doi: 10.1677/JOE-08-0507 PMID: 19398497
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 2012; 8: 728-742.
15. Gardiner SM, March JE, Kemp PA, Bennett T. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006; 316: 852-859. PMID: 16221740
16. Bojanowska E, Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7- 36) amide on release of neurohypophysial hormones and blood pressure in the rat. Reg Pept 2000; 91: 75-81.
17. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135. PMID: 12777949
18. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010; 59: 1063-1073. doi: 10.2337/db09-0955 PMID: 20097729
19. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256-2263. doi: 10.1007/s00125-010-1831-8 PMID: 20593161
20. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, et al. Exendin-4, a glucagon-like peptide-1. receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011; 405: 79-84. doi: 10.1016/j.bbrc.2010.12.131 PMID: 21215253
21. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J Biol Chem 2000; 275: 11706-11712. PMID: 10766791
22. Kobayashi S, Akiyama T, Nata K, Abe M, Tajima M, Shervani NJ, et al. Identification of a receptor for reg (regenerating gene) protein, a pancreatic beta-cell regeneration factor. J Biol Chem 2000; 275: 10723-10726. PMID: 10753861
23. Akiyama T, Takasawa S, Nata K, Kobayashi S, Abe M, Shervani NJ, et al. Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation. Proc Natl Acad Sci USA 2001; 98: 48-53. PMID: 11134536
24. Yoshizumi M, Tsuchiya K, Suzaki Y, Kirima K, Kyaw M, Moon JH, et al. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. Biochem Biophys Res Commun 2002; 293: 1458-1465. PMID: 12054679
25. Xie C, Guo Y, Zhu T, Zhang J, Ma PX, Chen YE. Yap1 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. J Biol Chem 2012; 287: 14598-14605. doi: 10.1074/jbc.M111.329268 PMID: 22411986
26. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011; 54: 2649-2659. doi: 10.1007/s00125-011-2241-2 PMID: 21786155
27. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037. doi: 10.2337/db09-1694 PMID: 20068138
28. Kyaw M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, Fujita Y, et al. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 2004; 65: 832-841. PMID: 15044612
29. Kyotani Y, Zhao J, Tomita S, Nakayama H, Isosaki M, Uno M, et al. Olmesartan inhibits angiotensin IIInduced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways. J Pharmacol Sci 2010; 113: 161-168. PMID: 20508392
30. Yao HL, Gao FH, Li ZZ, Wu HX, Xu MD. Zhang Z, et al. Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2. Mol Cell Biochem 2012; 366: 355-362. doi: 10.1007/s11010-012-1315-x PMID: 22527942
31. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes/Metabol Res and Rev 2003; 19: 115-123.
32. Frodin M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB, et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. J Biol Chem 1995; 270: 7882-7889. PMID: 7713882
33. Zhao L, Li AQ, Zhou TF, Zhang MQ, Qin XM. Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol 2014; 307: C1130-1141. doi: 10.1152/ajpcell.00151.2014 PMID: 25298426
34. Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, Uematsu E, et al. Exendin-4, a glucagon-like peptide-1. receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 2013; 699: 106-111. doi: 10.1016/j.ejphar.2012.11.057 PMID: 23220706